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Mohammad A. Rafi ID , Paola Luzi, David A. Wenger* ID
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Introduction
Krabbe disease (KD) or globoid cell leukodystrophy 
(GLD; OMIM 245200) is an autosomal recessive disorder 
affecting myelination in the human patients. It is caused 
by the deficiency of galactocerebrosidase (GALC; EC 
3.2.1.46) activity resulting from mutations in the GALC 
gene.1 The incidence is about one in 100 000 births in 
the United States. While most human patients present 
in infancy or late infancy, later onset patients are also 
diagnosed. In addition to human patients, genetic 
mutations in the GALC gene have resulted in GLD 
in several animal species, including mice, dogs and 
rhesus monkeys.2 Affected animals also have very low 
GALC activity resulting in pathology similar to human 
patients. Colonies of these species have been established 
at various locations to use for treatment trials. These 
include bone marrow transplantation (BMT), enzyme 
replacement therapy, gene therapy via different routes 
of administration, substrate reduction therapy, chemical 
chaperone therapy, small molecule therapy including 
anti-inflammatory drugs and combinations of these 
approaches.3-21 These different approaches have resulted 
in variable degrees of success. Some of these trials only 
resulted in minimal extension of life, and significant 
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Abstract
Introduction: Krabbe disease (KD) is an 
autosomal recessive lysosomal disorder caused 
by mutations in the galactocerebrosidase 
(GALC) gene. This results in defective 
myelination in the peripheral and central 
nervous systems due to low GALC 
activity. Treatment at this time is limited 
to hematopoietic stem cell transplantation 
(HSCT) in pre-symptomatic individuals. 
While this treatment extends the lives of 
treated individuals, most have difficulty 
walking by the end of the first decade due to 
peripheral neuropathy. Studies in the murine model of KD, twitcher (twi) combining bone marrow 
transplantation (BMT) with AAVrh10-mGALC showed a great extension of life from 40 days to 
about 400 days, with some living a full life time.
Methods: In order to find the optimum conditions for dosing and timing of this combined 
treatment, twi mice were injected with five doses of AAVrh10-mGALC at different times after 
BMT. Survival, as well as GALC expression were monitored along with studies of sciatic nerve 
myelination and possible liver pathology.
Results: Dosing had a pronounced effect on survival and measured GALC activity. There was 
window of time after BMT to inject the viral vector and see similar results, however delaying both 
the BMT and the viral injection shortened the lifespans of the treated mice. Lowering the viral 
dose too much decreased the correction of the sciatic nerve myelination. There was no evidence 
for hepatic neoplasia.
Conclusion: These studies provide the conditions optimum for successfully treating the murine 
model of KD. There is some flexibility in dosing and timing to obtain a satisfactory outcome. These 
studies are critical to the planning of a human trial combining the “standard of care”, HSCT, with a 
single iv injection of AAVrh10-GALC.
Article Type:
Original Article
Article History:
Received: 2 Feb. 2020
Accepted: 17 Mar. 2020
ePublished: 24 Mar. 2020
Keywords:
Krabbe disease
AAVrh10 gene therapy 
Twitcher mice
Bone marrow transplantation 
Combined therapy
Myelination
Article Info
PRESS
TUOMS
BioImpacts
B
PRESS
TUOMS
BioImpacts
B
Rafi et al
BioImpacts, 2020, 10(2), 105-115106
less than 100 days. PND10 is when mice start to rapidly 
myelinate, they are bigger and a larger dose of vector can 
be given. This may also reflect more the delay in treating 
newborn infants before receiving a definitive diagnosis of 
KD after birth. 
The standard of care in pre-symptomatic infants and 
mildly affected later-onset patients with KD is HSCT.30,31 
While initial studies were done using bone marrow cells, 
more recently HSCs isolated from umbilical cord blood are 
being used. This greatly improves the chances of finding 
a suitable match for a given patient. While this treatment 
has been shown to increase the lifespan of treated patients, 
almost all treated patients present with difficulty walking 
by the end of the first decade of life and have problems 
with expressive language.32 The walking difficulties appear 
to be due to a failure of HSCT to adequately correct the 
peripheral nervous system. Our studies in twi mice 
using a single iv injection of AAVrh10 containing mouse 
GALC cDNA alone at about PND10 showed near normal 
myelination in sciatic nerves. Moreover, studies combining 
BMT with a single iv injection of AAVrh10-mGALC 
on PND10-11 showed great synergy with many treated 
mice still alive at 350 days at the time of publication.17 
This compares to the median survival of 75-80 days for 
BMT or AAVrh10-mGALC when given alone. In order to 
evaluate the dose of viral vector that would be effective 
and to determine the timing of the combined treatment 
and the time from the BMT to viral injection, additional 
studies were undertaken. Results presented here show that 
the dose of vector is critical to survival and that there is 
some flexibility in the timing to perform viral injection 
treatment after BMT. These studies are very important 
since the combination of HSCT, the standard of care in 
humans, with a single iv injection of AAVrh10-hGALC is 
being considered by the FDA for a human trial. 
Materials and Methods
Study design 
This study is a follow up of our previous studies on gene 
therapy in combination with BMT for the mouse model 
of the KD. While we and others have shown a synergistic 
effect of AAV gene therapy in combination with 
BMT,9,12,14,17,18,20,21 the focus of this study was to investigate 
treatment conditions for safe and more effective therapy. 
Experimental variables examined include viral dosage, 
timing for both viral injection and BMT and use of bone 
marrow cells from heterozygous donors.
Generation of AAVrh10-mGALC vector 
Construction of the viral vector used in this study was 
previously reported.16 Briefly, pCB7plasmid, an enhanced 
construction of AAV2 vector, was received from the 
Institute for Human Gene Therapy at the University 
of Pennsylvania. Mouse GALC cDNA was cloned into 
EcoRI site of this construct, downstream from the human 
CMV-enhancer/chicken β-actin hybrid promoter. The 
side effects and pathological events were noted. Other 
treatments involving multiple injections into the brain, 
BMT without myeloablation of the recipient and use of 
toxic chemicals for substrate reduction that probably will 
not be used in human patients. Obviously, because of the 
cost and ease of breeding, most of the therapy trials have 
been done using the twitcher (twi) mouse model. As early 
as 1984, Yeager et al3 demonstrated that transplantation 
of BM cells from wild type mice into twi mice resulted in 
an extension of life from about 40 days when untreated to 
about 80 days. Early studies were done using irradiation 
for myeloablation to prepare the mice for BMT. However, 
for several reasons busulfan is now more commonly used 
for myeloablation.22
The initial purification of human GALC and cloning 
of the human GALC cDNA by this laboratory in 199323, 
24 was followed by characterization of the gene in 1995.25 
This opened the way to additional studies including 
mutational analysis of patients. Over 250 disease-causing 
mutations have been identified in the GALC gene (http://
www.hgmd.cf.ac.uk). The identification of the disease-
causing mutations in the animal species has facilitated the 
establishment of colonies for research on the pathology 
and treatment of this disease. Having GALC clones has 
also led to in vitro and in vivo gene therapy studies. Initial 
studies showed that the GALC cDNA in a retroviral vector 
could transduce GALC-deficient cells resulting in supra-
normal GALC activity with no ill effects, and that GALC 
activity could be excreted by these cells and taken up by 
neighboring cells.26 The idea of cross correction is the basis 
for studies showing that transplanted or virally transduced 
cells can supply a missing enzyme to neighboring cells, 
especially in lysosomal disorders.27 Since that time several 
groups have placed the species-specific GALC cDNA into 
different viral vectors for in vivo gene therapy trials alone 
and in combination with other approaches. It appears that 
adeno-associated viral vectors are being used most often 
in animal studies for KD and other genetic disorders.28, 
29 In this laboratory AAVrh10 containing the mouse 
GALC cDNA is being used for gene therapy studies in twi 
mice.14,16,17 Initial studies using this vector involved intra-
cerebroventricular, intra-cerebellar and intra-venous (iv) 
injections on PND2.14 There was a significant extension 
of life when all three routes of administration were used; 
the median survival was about 100 days compared to 
40 days in untreated mice. There was clear evidence for 
GALC expression throughout the brain and improved 
myelination. Also, there was retention of walking, strength, 
and mobility until the end of life. While the results were 
positive they clearly were not good enough. Further 
studies using a single iv injection of AAVrh10-mGALC 
on PND10 showed dramatic improvement in central and 
peripheral nerve system myelination, an area significantly 
affected in human patients and animal models.16 Starting 
iv treatment on PND10 instead of PND2 resulted in a 
longer lifespan for the treated mice, although it was still 
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construct was sequenced and the integrity of the ITRs 
was confirmed by restriction enzyme analysis using 
SmaI and NcoI. The functionality of the construct was 
verified by in vitro cell transfection and measurement 
of GALC enzyme activity. The recombinant genome 
was cross-packaged into AAVrh10 capsid by utilizing a 
chimeric AAV2-Rep/AAV1-Cap and helper plasmids 
during a triple-transfection procedure.33,34 Viral packaging 
and purification were accomplished by the Institute 
for Human Gene Therapy and the vector was called 
AAVrh10-mGALC. Viral titer, was determined by PCR of 
the simian virus 40 poly(A) sequence.34,35 The viral titer 
of the vector batch of AAVrh10-mGALC in use is 6×1013 
genomic equivalents/mL. 
Animal procedures 
Studies in mice were performed in accordance with 
approved protocols from the Animal Care and Use 
Committee at Jefferson Medical College. Twi mice used 
in the study were originally obtained from the Jackson 
Laboratory. These mice with a W339X mutation in the 
GALC gene are in the C57BL/6 background. Genotyping 
of the mice was performed on PND1 using polymerase 
chain reaction (PCR) as previously described.14,36 Toe clips 
were used for mouse identification and DNA extraction. 
PCR fragments were digested with EcoRV and analyzed 
by electrophoresis on 2.5% MetaPhor agarose gel (Lonza 
Inc. Allendale, NJ, USA). Male and female mice were used 
arbitrarily, even before their sex could be determined. No 
sex-related differences in outcomes following treatment 
were noted. Transplanted animals were monitored daily 
for the first week for any signs of problem related to the 
procedure. They were monitored two to three times a 
week for the rest of their lives. Body weight was recorded 
weekly throughout their lives. Treated mice were allowed 
to survive as long as humanely possible or sacrificed at 
different time points for analysis. If deemed moribund 
(inactive and with unexpected weight loss) the mice were 
killed by carbon dioxide euthanasia and the age of death 
was recorded. 
Bone marrow transplantation 
The procedure for BMT was previously described.17 
Briefly, BMT recipient mice were myelo-suppressed 
using busulfan (Sigma, St. Louis, MO). A 3 mg/ml 
solution of busulfan was prepared by dissolving it in 
dimethylsulfoxide (30% of the final volume), and adding 
the remaining volume of sterile phosphate-buffered 
saline. Eight or 9-day-old affected mice (this small 
variability in injection times was due to the timing of 
births) were weighed, and 30 mg/kg of body weight of 
the busulfan solution was injected intraperitoneally (ip). 
BM cells from the syngeneic donor mice were obtained by 
flashing tibiae and femora using ice-cold Hepes buffered 
Hanks’ balanced salt solution (Mediatech, Manassas, VA). 
The cells were counted, centrifuged, and resuspended in 
Dulbecco's modified Eagle's medium. Twenty-four hours 
after busulfan injection, mice received an ip injection of 
3–4 × 107 BM cells in a total volume of 0.2 mL. For at 
least two weeks after BMT, the mice were provided with 
prophylactic Neomycin (final concentration 500 μg/mL) 
(Sigma) in drinking water. Mice that received BMT and 
died less than PND30 were not included in these studies. 
Initially BM cells from non-carrier donors were used, but 
in some later studies BM cells from carrier mice were used.
Viral delivery 
The young mice were cryo-anesthetized on ice before the 
injections. Injections were carried out on a light box to 
facilitate visualizing the tail vein. In our original publication 
a total of 4 × 1013 gc/kg body weight of virus were injected 
into the tail vein using a 28G insulin syringe.17 The needle 
was inserted into the vein, and the solution containing the 
virus was injected manually. The success of injection was 
verified by noting blanching of the vein. The time for viral 
injection was between PND10 and PND40 depending the 
parameter to be investigated. After the injection, pups 
were warmed and returned to their cage. Mice that died 
within a few days of the injection (less than 10%) were not 
included in this study.
Tissue preparation for GALC assay 
Tissues from treated and untreated mice were removed 
immediately after carbon dioxide euthanasia. The tissues 
were quickly frozen and stored at −80°C or immediately 
homogenized in distilled water using a Polytron apparatus 
(Brinkmann Instruments, Westbury, NY). Protein 
concentration was determined according to the method 
of Lowry et al.37 GALC activity was measured using [3H]
galactosylceramide substrate, according to our published 
method.38 GALC activity was expressed as nmol substrate 
hydrolyzed/h/mg protein.
Preparation of semi-thin sections of sciatic nerves and 
toluidine blue staining
Treated and control mice were sacrificed by carbon dioxide 
euthanasia. Sciatic nerves were removed and submerged 
into 2% glutaraldehyde in 0.1M phosphate buffer, pH 7.4, 
followed by post-fixation in 1% osmium tetroxide in 0.1M 
phosphate buffer. The tissue fragments were dehydrated 
in series of graded ethanol penetrated with mixtures of 
embedding medium (Spurr) and ethanol and polymerized 
over night at 80°C. Semi-thin (0.5 micron) sections were 
cut on a UC7 ultramicrotome (Leica Microsystems, 
Wetzlar, Germany), using glass knives. The sections were 
transferred to glass microscopic slides, and stained with 
Toluidine Blue O.
Hematoxylin and eosin stain of liver sections 
Livers were removed from untreated and treated mice, 
fixed in 10% formalin and paraffin-embedded. Four 
micrometers thick sections were cut on a microtome 
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at room temperature, mounted on Superfrost Plus 
microscope slides (Thermo-Fisher Scientific), and air-
dried. Sections were de-paraffinized in xylene, re-hydrated 
in a series of graded ethanol, and distilled water. Sections 
were stained with hematoxylin and eosin (H&E) using the 
manufacturer’s protocol. After staining and final washes, 
slides were mounted in ProlongGold (Life Technologies) 
and covered with a coverslip for examination.
Statistical analysis 
Survival analysis was performed using GraphPad Prism 
7.0 software (GraphPad software Inc., San Diego, USA). 
The survival curves were analyzed using the log-rank 
(Mantel-Cox) test. The survival rates of all experimental 
groups were compared to our previously published 
method where the mice received BMT around PND10 
and iv viral injection (4 × 1013 gc/kg body weight) on the 
following day. GALC activity of the CNS and PNS of the 
mice treated with different viral doses were compared to 
the standard viral dose using two-tailed, unpaired t test (* 
P < 0.05, **P < 0.01, *** P < 0.001, **** P < 0.0001).
Results
Update on the previously published method of treatment 
combining BMT and iv AAVrh10-mGALC 
Intra-peritoneal (ip) injection of the affected mice at 
PND9 with busulfan (30 mg/kg body weight) was followed 
after 24 hours by an ip injection of 3-4 × 107 bone marrow 
cells from non-carrier syngeneic mice. The following 
day mice received an iv injection of 4 × 1013 gc/kg body 
weight (called 1X dose) of AAVrh10-mGALC [17]. At 
the time of that publication most of the treated mice were 
still living, and additional mice were treated in the same 
manner. On Fig. 1 the survival of untreated twi mice and 
mice treated with combined therapy are compared to mice 
receiving BMT alone or AAVrh10 alone. As can be seen on 
the figure the median age of survival of the mice treated 
with combined therapy is nearly 400 days with some living 
over 500 days compared to 40 days if untreated. Due to 
the known tropism of AAVrh10, the heart was found 
to have the highest GALC activity followed by skeletal 
muscle, liver, sciatic nerve, spinal cord and cerebellum 
using the standard dosing and timing (Fig. 2A and B, 
black bar). However, while the GALC activities measured 
in nervous tissues are lower than heart, liver and muscle 
they are within the range measured in wild type mice and 
well above the very low activity measured in untreated 
twi mice. The GALC activities are maintained in all tested 
tissues for the life of the treated mice (Table 1). 
As shown in the previous publication17 luxol fast blue/
periodic acid Schiff (LFB/PAS) staining showed normal 
myelination of the CNS and PNS for the lives of the 
treated mice. Grossly the sciatic nerves of the untreated 
twi mice are enlarged due to edema (Fig. 3B), while they 
look thin like normal in twi mice receiving BMT plus AAV 
(Fig. 3C). The lack of normal myelination plus edema is 
confirmed on toluidine blue stained semi-thin sections 
of sciatic nerve from an untreated twi mouse (Fig. 4B) 
compared to a wild type mouse (Fig. 4A). A 606-day-old 
twi mouse treated with combined therapy using standard 
dosing and timing shows normal myelinated axons with 
no edema (Fig. 4C). Normal myelination in the sciatic 
Fig. 1. Effect of different treatment strategy on twi mice. Survival of twi 
mice either untreated, treated with BMT only, AAVrh10-mGALC only and 
combined BMT plus AAVrh10-mGALC on PND10/11 using the standard 1X 
dose. ****P < 0.0001.
Fig. 2. Effect of the viral dose on GALC activity of different tissues 
in twi mice. All BMT and viral injections were performed on PND10/11. 
(A) GALC activities in brain, cerebellum, spinal cord and sciatic nerve of 
twi mice receiving BMT and the standard 1X dose of vector are shown by 
the solid black bar (n=11-13). The following viral doses were used: 1/2X 
(n=6), 1/10X (n=4), 1/100X (n=5) and 4X (n=12-13). GALC activities were 
compared to the standard dose. Two-tailed, unpaired t test was used for 
statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (B) 
Effect of the viral dose on GALC activities of heart, skeletal muscle and 
liver is compared with our standard treatment (black bar). As shown in the 
figure, the GALC activity of the heart was highest compared to skeletal 
muscle and liver. As the GALC activities were so high in these tissues 
compared to the untreated twi mice and wild type mice statistical analysis 
was not performed. The mean and SEM is presented. 
**** ****
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nerve is important as this tissue is not corrected by HSCT 
alone in human patients and twi mice.
Effect of viral dose following BMT on survival, GALC 
activity and myelination of twi mice
In order to see the effect of viral dose on survival, different 
doses of AAVrh10-mGALC were injected iv 24 hours 
following BMT as described above. Initial studies were 
done using the following viral doses: 4 × 1013 (1X), 2 × 
1013(1/2X), 4 × 1012 (1/10X) and 4 × 1011 (1/100X) gc/
kg body weight. The p values compare the survival of 
mice receiving different viral doses to the standard dose 
(1X). As can be seen on Fig. 5A injecting one-half of the 
published viral dose the median survival dropped to about 
180 days (P = 0.01) about half of the median survival when 
the standard dose was used. When one-tenth of the usual 
dose was used the median survival was only about 80 
days (P = 0.0001), and when one-hundredth of the usual 
dose was used there was essentially no effect on survival 
beyond untreated or BMT-treated twi mice showing the 
dramatic effect of viral dose on survival. When the dose 
of viral vector was increased to four times the published 
dose, now 1.6 × 1014 (4X), the median survival, while not 
statistically significant, was over 500 days, again showing 
the importance of viral dose on survival after BMT in the 
twi mice.
In addition to the decreased survival with a viral dose 
lower than the standard dose, there was a decrease in 
GALC activity in the tissues tested (Fig. 2A, B). P values 
presented on the figure compare the GALC activities 
measured with the standard dose (1X) to the activities 
measured with changes in the viral dose. The effects of 
viral dose following BMT on GALC activities in nervous 
tissues are shown on Fig. 2A. There was a statistically 
significant drop in GALC activity in brain, cerebellum 
and spinal cord with the 1/2X, 1/10X and 1/100X doses. In 
sciatic nerve the GALC activities measured were also lower 
at the smaller vector doses although they only reached 
statistical significance at the 1/10 and 1/100X doses. When 
the 4X dose was injected following BMT, GALC activities 
were increased in all nervous tissues but did not reach 
statistical significance in the spinal cord and sciatic nerve. 
However, all doses resulted in much higher GALC activity 
than untreated twi. These results show the ability of this 
treatment to bring GALC activity to the needed tissues. 
As expected, due to the tropism of AAVrh10, high GALC 
activity was measured in heart, liver and skeletal muscle 
(Fig. 2B). Very high GALC activity was measured in those 
tissues using the three highest viral doses.
The condition of the sciatic nerve myelin was examined 
using toluidine blue staining. Using the standard dose 
of viral vector the sciatic nerve myelin looks normal in 
a 606-day-old mouse (Fig. 4C) and a 239-day-old mouse 
that received 4X the standard dose (Fig. 4D). The myelin 
looks slightly less normal when 1/2X dose was used (Fig. 
4E) and very abnormal when only 1/100X dose was 
injected (Fig. 4F). The results clearly show that the dose of 
AAVrh10-mGALC after BMT is critical to overall survival 
as well as the health of the myelin in sciatic nerve.
Effect of the timing of the viral injection following BMT 
on PND10 
Initially twi mice were given busulfan on PND 9-10 
and BMT the next day followed 24 hours later by an iv 
injection of the viral vector.17 However, in this study the 
standard dose of virus was injected five days, ten days or 
30 days after the BMT. As can be seen in Fig. 5B, there was 
no significant difference in survival when the viral vector 
was injected five and 10 days after the BMT compared 
to one day after BMT. The sciatic nerve myelin looked 
completely normal when the viral vector was injected five 
days after BMT (Fig. 4G) but less than completely normal 
when injected 10 days after BMT (Fig. 4H). However, the 
Fig. 3. Gross appearance of sciatic nerves in wild type and 
untreated and treated twi mice. (A) Sciatic nerves from a 60-day-old 
wild type mouse. (B) 37-day-old untreated twi mouse. (C) 250-day-old 
mouse treated with both BMT and AAVrh10-mGALC on PND10/11 using 
the standard 1X dose.
Table 1. GALC activitya of different organs at different ages of mice treated with BMT and 1X AAV
Mice age (days) Number of mice
Tissues
 Brain Sciatic nerve  Liver  Heart
100-300 n=3 0.7-1.9 - 5.6-47.0 111.0-625.1
300-500 n=5 0.7-2.2 1.3-2.3 14.5-37.9 396.6-712.2
500-750 n=3-5 1.1-3.6 2.7-6.5 31.0-75.0 238.8-627.8
a nmol/h/mg protein.
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lifespans of the treated mice at these two time points were 
very similar (Fig. 5B). Injecting the virus 30 days after 
the BMT (PND40) resulted in a poor outcome, with the 
median survival near that of mice receiving BMT alone 
with only a few mice living more than 100 days (Fig. 
5B). The GALC activities in the tissues of the mice in the 
timing study are presented on Table 2. At all-time points 
of viral injection there is high GALC activity in heart and 
liver and less, but significant, activity in brain and sciatic 
nerve. These studies indicate that damage to the nervous 
system must have occurred before the increase in GALC 
activity was provided by the injections of viral vector.
The question of how long does it take after vector 
injection to measure GALC expression in different tissues 
was answered by iv injection of 4 × 1013 gc/kg virus on 
PND11 with or without BMT into twi mice. Samples 
of heart, liver, brain and sciatic nerve were taken from 
sacrificed mice and assayed for GALC activity 24, 48, 72 
and 96 hours after viral injection. As can be seen on Table 
3 higher than normal GALC activity was measured after 
only 48 hours in heart and liver. Normal GALC activity 
could be measured in sciatic nerve after 48 hours, and 
Fig. 4. Toluidine blue-stained semi-thin sections of sciatic nerves from wild type and untreated and treated twi mice. (A) 62-day-old wild type mouse. 
(B) 36-day-old untreated twi mouse. (C) 606-day-old twi mouse treated with AAVrh10 (1X dose) on PND11. (D) 236-day-old twi mouse treated with AAVrh10-
GALC (4X dose) on PND11. (E) 235-day-old twi mouse treated with AAVrh10 (1/2X dose) on PND11. (F) 50-day-old twi mouse treated with AAVrh10 (1/100X 
dose) on PND11. (G) 332-day-old twi mouse treated with AAVrh10 (1X dose) on PND15. (H) 420-day-old twi mouse treated with AAVrh10 (1X dose) on 
PND20. All treated mice received BMT on PND10 followed by a single iv viral injection. Original magnification is 400X. 
Fig. 5. Survival of twi mice either untreated or treated under different conditions. 
(A) Effect of viral dose on survival. (B) Effect of timing of viral injection (1X dose) after BMT on PND11. (C) Effect of doing both BMT and viral injection (1X 
dose) at a later time point. (D) Effect of using heterozygote donors for BMT followed by AAVrh10 (1X dose) on PND11. The survival curves were analyzed 
using the log-rank test. The survival of all experimental groups were compared to the standard method (solid blue color). **P < 0.01, ****P < 0.0001. 
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supranormal GALC activity could be measured after 72 
hours. Busulfan treatment and BMT had no effect on the 
rapid increase in GALC activity in the tissues analyzed.
Effect on survival when both BMT and viral injection are 
performed later 
When treatment with busulfan and BMT were delayed 
until about PND17 and AAVrh10-GALC was injected the 
following day there appeared to be a drop in the median 
age of survival compared to when BMT plus AAVrh10 
injection was performed about PND10-11, although it 
did not reach statistical significance (Fig. 5C). If the start 
of treatment was delayed until PND19-20 or PND21-22 
there was a very significant drop in survival to less than 
100 days. Since the tremor in untreated twi mice begins 
on about PND20 it appears that starting treatment too 
close to that age is not as effective as starting treatment at 
a younger age. This highlights the importance of starting 
BMT at a young age. Even, as shown above, GALC activity 
can be measured in critical tissues very rapidly after iv 
injection, it may be too late to correct damage that has 
already occurred.
Effect when bone marrow cells from heterozygous donors 
are used for transplantation before viral injection
 Studies in humans show that HSCT alone has a positive 
effect on lifespan and partial correction or stabilization 
of some neurodiagnostic parameters. The effect of HSCT 
alone is more successful in human patients with survival 
into the second decade possible following HSCT if the 
individual is treated when pre-symptomatic or very early 
symptomatic.32 BMT treatment alone in twi mice extends 
their lives from about 40 days to about 80 days, which 
is not as great of an effect as seen in human patients. In 
most human patients the HSC donor is a closely human 
leukocyte antigen (HLA) matched allogeneic donor 
obtained from umbilical cord blood. In some cases, HSC 
from a related donor is used. In either case, it is ideal for the 
donor to have good GALC activity so that engrafted cells 
can donate GALC activity to neighboring cells. In addition 
to these donor HSCs providing a source of GALC activity 
it is thought that they also have an anti-inflammatory 
component. However, it is possible with the increasingly 
diverse human population in the United States that a 
suitable allogeneic donor may not be available. A relative 
who is a suitable HLA match but is a carrier of KD may 
be the best option. Since AAVrh10-mGALC has a strong 
synergistic effect when combined with BMT in the mice, 
and the AAVrh10-GALC provides more GALC activity 
than the BMT, it was thought that using heterozygous 
donor mice as a source of BM cells would be equally as 
good as non-carrier donors. As shown on Fig. 5D, the use 
of BM cells from carriers lowered the median survival to 
less than 200 days. The survival was similar to the survival 
observed when half of the usual dose of AAVrh10 was used 
in combination with BMT (Fig. 5A). However, the GALC 
activities in the tissues from the twi mice treated using 
BM cells from heterozygous donors and gene therapy are 
similar to values measured in tissues from twi mice treated 
using non-carrier donors (data not shown). While this is 
an interesting finding in the twi mice, its relevance to the 
use of carrier donors in humans is still open to question. It 
is also well known that there are common polymorphisms 
in the GALC gene that lower the GALC activity measured 
in leukocytes to values measured in obligate carriers. It is 
probable that some human patients receiving HSCT were 
transplanted with HSC from a donor having one or more 
of these enzyme-lowering polymorphisms. What effect 
this has on overall outcome is not known.
Table 2. Effect of viral injection time on GALC activitya of the different tissues
BMT & Viral injection time B Brain Sciatic nerve Liver Heart Muscle Age  (days)
Untreated affected, n = 6 0.24 (0.0-0.6) 0.2  (0.1-0.3) 0.5  (0.1-0.8) 0.5 (0.2-1.1) 0.5 (0.0-1.3) 30-45
Wild type, n = 4-6 1.8 (1.0-2.5) 1.2 (0.7-2.0) 1.9 (1.2-2.6) 0.6 (0.3-0.8) 0.4 (0.4-0.6) 32-90
AAV @ PND11-12, n=11-13 1.7 (0.5-3.6) 3.4 (1.3-8.6) 33.1 (13.0-75.0) 516.0 (140.0-758.0) 161.7 (51.0-433.2) 263-754
AAV @ PND15, n=5 2.0 (1.3-2.6) 7.9 (2.3-22.9) 73.0 (35.7-159.0) 550.1 (218.9-764.0) 124.7 (22.9-247.5) 90-647
AAV @ PND20, n=7 1.8 (0.8-3.4) 3.5 (1.5-5.4) 60.0 (18.4-100.7) 421.0 (95.9-657.6) 94.4 (9.5-222.2) 233-495
AAV @ PND40, =4 1.1 (0.7-1.7) 3.5 (1.2-3.6) 135.0 (70.5-255.7) 218.0 (115.4-324.2) 9.1 (2.7-12.7) 53-287
a nmol/h/mg protein expressed as mean and range. 
b All treated mice received BMT on PND10 followed by 1X viral dose at different times.
Table 3. Time of GALC expressiona after iv injection of AAVrh10-mGALC on PND11
Organ 24 h 48 h 72 h 96 h Untreated twi mice Wild type
Brain 0.3, 0.3 0.4, 0.2, 0.4 b 0.6, 0.7 1.1 b, 1.5 b 0-0.1 1.0-3.6
Sciatic nerve 0, 0.2 2.2, 1.9, 1.9 b 5.5, 7.9 17.2 b, 41.1 b 0-0.2 0.7, 2.0
Liver 0.8, 0.9 14.2, 20.6, 20.7 b 18.0, 36.9 58.8 b, 71.8 b 0.1-0.3 1.7, 4.4
Heart 0.4, 0.4 13.1, 11.2, 12.3 b 23.8, 28.8 70.4 b, 65.3 b 0.3-0.6 0.4-2.1
a nmol/h/mg protein; b These mice also received BMT on PND10.
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Pathological examination of liver sections from treated 
twi mice 
In twi mice treated with combined BMT and iv gene therapy 
that died or were sacrificed less than 300 days of age all 
organs appeared normal on gross examination, including 
the heart and liver with high GALC activity. Liver samples 
from mice treated by different methods were taken, sliced 
and stained with H&E for pathological examination. 
While most regions of the liver samples from long-living 
treated mice appeared normal (Fig. 6A), pathological 
changes were noted in the livers of a few animals, notably 
dilated sinusoids (Fig. 6B), hepatocellular hyperplasia 
(Fig. 6C) and presence of vacuolar cytoplasmic aggregates 
(Fig. 6D). Rare foci of extra-medullary hematopoiesis 
were also noted. Similar changes have been reported in 
some patients receiving blood stem cell transplantation 
and with other hematological disorders.39 There have 
been reports of hepatocellular carcinoma in livers of mice 
treated with AAV vectors.40-43 However, the examination 
of liver tissues from over 50 treated mice showed no 
evidence of neoplastic changes. 
Discussion
The naturally occurring twi mouse has proven to be an 
excellent model to study the pathology and treatment of 
KD. It has a mutation causing a premature stop codon 
resulting in little if any GALC protein to be made.36 Mice 
homozygous for this mutation die by about 40 days and are 
not fertile. Since the initial attempt at treating this model 
with BMT by Yeager and colleagues,3 many other attempts 
have been made using a variety of procedures and drugs. 
Without referencing all of the literature, it appears that 
some type of combined therapy involving BMT and gene 
therapy is the best option at this time. In some studies, 
multiple injections into the brain, additional drugs and 
irradiation before BMT were used but these methods 
may not be applicable for a human trial. HSCT in pre-
symptomatic infants predicted to develop KD has shown 
the most promise in slowing the course of the disease while 
preserving most of cognitive function.32 However, by the 
end of the first decade almost all of the treated individuals 
show significant peripheral neuropathy. Therefore, 
adding a simple gene therapy treatment to HSCT to help 
with that aspect would be most advantageous. Studies 
in twi mice combining BMT with AAV gene therapy 
show great promise in that regard. A number of viral 
vectors available for gene therapy trials using different 
routes of administration are showing promise in treating 
neurodegenerative disorders.33-35 The use of a single iv 
injection of AAVrh10-mGALC following HSCT seems 
to be the least complicated therapy to implement. Also 
HSCT is already considered the “standard of care” for 
pre-symptomatic individuals. As shown herein, there is 
some flexibility in dosing and timing that would permit 
adaption to a human trial.
When the mice received a single iv injection of AAVrh10-
mGALC in PND10 they showed normal or supranormal 
GALC activity in all tissues analyzed, including brain, 
spinal cord and sciatic nerve.16 LFB/PAS staining showed 
normal myelination in the cerebrum, spinal cord and 
sciatic nerve. The median survival of these mice was 72 
days with only one living more than 100 days. This was 
better than twi mice receiving the iv injection at PND2.14 
Clearly twi mice need more than just high GALC activity 
to live longer lives. Most infantile human patients treated 
before five weeks of age can live at least into the second 
Figure 6. Hematoxylin and eosin staining of liver sections.  (A) 606-day-old twi mouse treated with BMT plus 1X AAVrh10-mGALC on PND10/11 
showing normal morphology. (B) 606-day-old twi treated with BMT and 1X AAVrh10-mGALC on PND10/11 showing dilated sinusoids. (C) 754-day-old twi 
mouse treated with BMT plus 1X AAVrh10-mGALC on PND10/11 showing hepatocellular hyperplasia. (D) 472-day-old twi mouse treated with BMT plus 1/2X 
AAVrh10-mGALC on PND10/11 showing vacuolar changes.  The original images are 10X and the inserts are 20X.  
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decade with only HSCT. That treatment only provides a 
relatively small amount of GALC activity to the tissues, 
therefore the HSCs must provide an additional component 
to the treatment. BMT of twi mice has been shown to 
slightly lower the psychosine concentration in brain but 
not sciatic nerves.44 However, it has been shown to lower 
many cytokines and chemokines in brain related to the 
inflammatory component of this disease.10 Therefore 
combining BMT with iv injection of AAVrh10-GALC 
seems to offer the best option for successful treatment of 
this disease at this time. 
When our initial studies combining BMT with a single 
iv injection of AAVrh10-mGALC were published most of 
the treated twi mice were still living.17 Additional mice 
were treated the same way. Since that time most of those 
mice given our published dose of 4 ×1013 gc/kg on PND10-
11 have died. The median survival is 389 days and with 
some living over 500 days. The studies reported here show 
that the survival is related to the dose of AAVrh10 vector; 
when less vector than used in the original paper was 
injected after BMT the survival rate dropped significantly 
as shown on Fig. 5A. In addition, the use of lower doses of 
vector compared to the standard dose resulted statistically 
lower levels of GALC activity in brain, cerebellum and 
spinal cord (Fig. 2A). When 4X vector was injected 
on PND10 the median survival appeared to increased 
further although it did not reach statistical significance. 
The higher vector dose resulted in more GALC activity 
measured in all nervous tissues although it did not reach 
statistical significance in spinal cord and sciatic nerve 
(Fig. 2A). These results clearly show that vector dose has a 
significant effect on outcome.
The initial studies combining BMT with iv AAVrh10 
were done starting at PND9 with busulfan injection, 
followed by BMT the next day and viral injection the 
following day. The data presented here show that delaying 
the viral injection by 5 or 10 days had no significant effect 
on the median survival of these mice (Fig. 5B). This may 
not be surprising since it has been shown that BMT alone 
at PND10 can prolong the lives of twi mice to an average 
of about 80 days (Fig. 1) which agrees with the study of 
Yeager et al.3 It can also be shown that there is a small 
increase in GALC activity in CNS with BMT treatment 
alone at least in young mice. However, some earlier 
studies were done using irradiation for myelo-suppression 
which may disrupt membrane integrity. Also, there may 
not be a need for much GALC activity before PND10 in 
mice as myelin is just being laid on newly formed axons. 
When the time for viral injection is delayed to 30 days 
following BMT (PND40), the survival is very similar to 
BMT alone, although a few mice lived more than 100 days 
(Fig. 5B). After PND20, when the untreated twi mice start 
to have tremors, and the sciatic nerves of twi mice treated 
only with BMT have abnormal pathology, there is a need 
for more GALC activity provided by the viral vector to 
correct the myelination in the PNS. Studies injecting the 
viral vector 20 days after BMT (PND30) are underway but 
the mice are too young to reach a conclusion regarding 
the latest time point that can still result in a lifespan near 
that of mice that received viral injections on PND10-11, 
PND15 and PND20. While starting the BMT around 
PND10 followed by viral injection one, five or ten days 
later was found to be satisfactory, additional studies 
were done delaying both the BMT and viral injection to 
PND17-18, PND19-20 and PND21-22. The experiments 
show that delaying the start of both treatments resulted in 
overall shortened survival (Fig. 5C). While these studies 
in mice may have little relevance to the timing of viral 
injection in human patients following HSCT, they do 
show that timing should be considered when planning a 
clinical trial. Our studies show that GALC expression is 
detected within 48 hours following iv injection (Table 3). 
This is important to the successful treatment of a severe 
genetic disease that can have a rapid downhill course. 
The studies utilizing heterozygous mice as BM donors 
were performed to determine if the outcomes were 
comparable to those receiving BM from non-carrier 
BM donors. This was done for several reasons. (1) To 
determine if the GALC activity in the carrier bone marrow 
cells, which might be about half of that from non-carrier 
mice, worked as well in prolonging life when combined 
with viral gene therapy. (2) To provide some insight as to 
the question of whether human related donors who are 
carriers of mutations in the GALC gene would be suitable 
to be used as an HSC donor. BM cells from heterozygous 
donors should still provide the anti-inflammatory 
component to the treatment since carriers of KD have 
no obvious clinical issues while the viral vector should 
provide adequate GALC activity. At least in twi mice, it 
appears that using BM cells from carrier mice plus iv gene 
therapy did not result in the lifespans observed when BM 
cells from non-carrier mice were used (Fig. 5D). However, 
it may not be true for all human families. In some families 
only a related donor is a good HLA match for the patient 
and will be used for HSCT regardless of carrier status. 
Also, since there is a high frequency of GALC activity 
lowering polymorphisms in the “normal” GALC gene, 
some recipients of HSCT are receiving bone marrow cells 
from donors with GALC activity within the wide carrier 
range.
There is controversy regarding the increase in the 
incidence of hepatocellular carcinoma in livers of mice 
treated with AAV vectors.40-43 However, in our study there 
were no significant pathological changes in mice living 
less than 300 days. Most regions of the liver samples 
from long-living treated mice appeared normal, however, 
some pathological changes were noted in the livers of a 
few animals, notably dilated sinusoids, hepatocellular 
hyperplasia and presence of vacuolar cytoplasmic 
aggregates. While some rare foci of extra-medullary 
hematopoiesis were noted, similar changes have been 
reported in some patients receiving blood stem cell 
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What is the current knowledge?
√ Krabbe disease (KD) is an autosomal recessive lysosomal 
disorder.
√ KD is caused by mutations in the galactocerebrosidase 
(GALC) gene. 
√ Low GALC activity causes defective myelination in the 
peripheral and central nervous systems.
√ Hematopoietic stem cell transplantation (HSCT) in pre-
symptomatic individuals is the only effective treatment. 
√ HSCT extends the lives of treated individuals, while most 
have difficulty walking by the end of the first decade due to 
peripheral neuropathy. 
What is new here?
√ Combining BMT with a single iv injection of AAVrh10-
mGALC greatly extends the lives of twitcher (twi) mice, a 
murine model of KD. 
√ The dose of viral vector has a profound effect on survival 
and measured GALC activity. 
√ Delaying both the BMT and the viral injection can shorten 
the lifespans of the treated mice.
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transplantation and with other hematological disorders.39 
However, the examination of liver tissues from over 50 
treated mice showed no evidence of neoplastic changes. 
Conclusion
It is commonly assumed that earlier is better when 
it comes to instituting any type of therapy in human 
patients, especially in those disorders involving significant 
neurologic involvement. That is done to prevent 
pathological changes in the CNS and PNS before they 
become irreversible. For this reason newborn screening 
(NBS) for some genetic disorders, including KD, has been 
started in several states.45 This is being done to identify 
individuals who will develop a given disease before 
clinical features appear and before there is significant 
damage to the developing nervous systems. NBS tests 
that were developed to identify individuals at a “high 
risk” for developing infantile disease have been mostly 
successful. However, there are still issues relating to onset, 
predicting the severity of the disease, and timing to start 
treatment to be settled. There may be delays in making 
a conclusive diagnosis as to the type of disease (infantile, 
late infantile, or late-onset) and in finding a suitable donor 
for HSCT. The more we can learn from the animal models 
related to dosing, timing and donor status, the better the 
outcomes for treating human patients will be. It appears 
that combining a single iv injection of AAVrh10-GALC 
following HSCT, the current standard of care, offers 
the best hope for the individuals found to be at risk for 
developing KD.
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